100 CAMPUS DRIVE, FLORHAM PARK, NJ
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Earnings Release
Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refract
Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Other Events
News, Articles of Incorporation
Announces One-for-Thirty Reverse Stock Split
FY 2025
Q3
Q2
Q1
FY 2024
Notice of Late Filing for Quarterly Report
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Direct Registration System
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload